Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Monalizumab by Innate Pharma for Small-Cell Lung Cancer: Likelihood of Approval
Monalizumab is under clinical development by Innate Pharma and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData,...
Data Insights
Risk adjusted net present value: What is the current valuation of AstraZeneca's Monalizumab?
Monalizumab is a monoclonal antibody commercialized by AstraZeneca, with a leading Phase III program in Non-Small Cell Lung Cancer. According...